Investor Presentaiton
Investor presentation
First three months of 2017
Slide 95
NovoSevenⓇ
-
a unique biologic for the treatment of rare
bleeding disorders
DKK
billion
3.0
2.5
2.0
1.5
1.0
0.5
0.0
NovoSevenⓇ reported quarterly sales
Q1
2012
CAGR¹ 3.9%
•
•
Key NovoSeven® properties
Product characteristics: powder and solvent for solution
for intravenous injection, available in multiple doses, stable
at room temperature
MixProⓇ administration system launched in 2013
Indications: treatment of spontaneous and surgical
bleedings in:
•
Haemophilia A or B patients with inhibitors
•
Acquired haemophilia
•
Congenital FVII deficiency
Q1
2017
• Glanzmann's thrombasthenia²
1 CAGR for 5-year period
changing
diabetes
2 Only indicated in Europe and the US
novo nordiskView entire presentation